<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/21CFR50.html">Part 50
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 50.54  Clinical investigations not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the
                            </h3>
                            <p class="depth0">If an IRB does not believe that a clinical investigation within the scope described in Sec. Sec. 50.1 and 56.101 of this chapter and involving children as subjects meets the requirements of Sec. 50.51, Sec. 50.52, or Sec. 50.53, the clinical investigation may proceed only if:</p><p class="depth1"><em>(a)</em> The IRB finds that the clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and</p><p class="depth1"><em>(b)</em> The Commissioner of Food and Drugs, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and following opportunity for public review and comment, determines either:</p><p class="depth2"><em>(1)</em> That the clinical investigation in fact satisfies the conditions of Sec. 50.51, Sec. 50.52, or Sec. 50.53, as applicable, or</p><p class="depth2"><em>(2)</em> That the following conditions are met:</p><p class="depth3"><em>(i)</em> The clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children;</p><p class="depth3"><em>(ii)</em> The clinical investigation will be conducted in accordance with sound ethical principles; and</p><p class="depth3"><em>(iii)</em> Adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians as set forth in Sec. 50.55.
[66 FR 20598, Apr. 24, 2001, as amended at 78 FR 12951, Feb. 26, 2013]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
